Histological Alterations Induced by Atorvastatin Therapeutic Doses in some Organs of Male Albino Rats

Authors

  • Twana Mustafa Department of Med. Lab Technique, Erbil Polytechnic University, Health Technical College, Erbil, Iraqi Kurdistan, 2 Department of Histopathology, Shar Hospital, Sulaimania, Kurdistan Region - F.R. Iraq
  • Hamza Abdulah Department of Med. Lab Technique, Erbil Polytechnic University, Health Technical College, Erbil, Iraqi Kurdistan, 2 Department of Histopathology, Shar Hospital, Sulaimania, Kurdistan Region - F.R. Iraq

DOI:

https://doi.org/10.25156/ptj.v9n1y2019.pp13-16

Keywords:

Atorvastatin, Kidney, Liver, Rats, Testis

Abstract

Vascular disease and heart attacks are a common phenomenon in the modern world, where lipid accumulates inside blood vessels and causes plug, eventually heart stroke and death. Utilize lipidlowering drugs are the most effective factors to prevent heart disease. Atorvastatin is the most important drugs that used in this field. The aim of this study was to investigate the adverse effects of atorvastatin (20 mg/kg/b.wt/day) on some organs of albino. 12 adult male albino rats weighing 200 ± 20 g were used and divided into two groups: First group served as control group, was given 0.72 ml distilled water/rat. The second group was subjected to treatments with atorvastatin in a dose of 20 mg/kg/b.wt/day as a single daily dose (0.72 ml contained 1.44 mg of atorvastatin) orally by gastric tube for 4 weeks. Histological alterations were examined, and the results of atorvastatintreated groups showed changes in the kidney sections, which include focal tubular edema and glomerular atrophy, also liver sections revealed foci of lymphocyte accumulation, cytoplasmic vacuolization, as well as sections of the testes showed degenerative changes in the seminiferous tubules. According to this study, we can conclude that atorvastatin-induced various deleterious changes in the histological structure of the testes, kidneys and cause mild liver alteration of adult male albino rat.

Downloads

Download data is not yet available.

References

Bancroft, J. D. and M. Gamble. 2008. Theory and Practice of Histological Techniques. 6th ed. Churchill Livingstone, London. p340-348.

Bosch, X. A., E. B. Poch and J. M. Grau. 2009. Rhabdomyolysis and acute kidney injury. N. Engl. J. Med. 361: 62-72.

Brugnon, F. 2014. Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: A pilot prospective clinical trial. Reprod. Biol. Endocrinol. 12(1): 1-12.

Brunton, L. L., B. A. Chabner and B. C. Knollmann. 2011. Goodman and Gilman’s: The Pharmacological Basis of Theraputics. 12th ed. McGraw Hill Medical, New York, Chicago and San Francisco. p877-878.

Goldstein, J. L. and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343: 425-30.

Hoofnagle, J. H. 2017. Identification and Characterization of Fenofibrate-Induced Liver Injury. Digestive Diseases and Sciences. Springer, US.

Jaikumkao, K., A. Pongchaidecha, N. Chattipakorn, V. Chatsudthipong, S. Promsan, P. Arjinajarn and A. Lungkaphin. 2016. Atorvastatin improves renal organic anion transporter 3 and renal function in gentamicin-induced nephrotoxicity in rats. Exp. Physiol. 101(6): 743-753.

Miller, M. 2009. Commentary dyslipidemia and cardiovascular risk: The importance of early prevention. QJM. 102(9): 657-667.

Mizugushi, Y., A. Miyajima, T. Kosaka, T. Asano and M. Hyakawa. 2004. Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J. Urol. Dec. 172(6): 2456-2459.

Mostafa, A., A. F. Mohammed and S. M. Hanafi. 2015. Effect of atorvastatin on the testis of adult male albino, Al Azhar Assiut Med. J. 13(4): 100-118.

Paget, G. C. and J. M. Barnes. 1964. Toxicity in Evaluation of the Drug Activities. Pharmacometric ed. Lournace and bacharachai. Academic press, London and New York. p1-13.

Pal, S., M. Ghosh, S. Ghosh, S. Bhattacharyya and P. C. Sil. 2015. Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways. Food Chem. Toxicol. 83: 36-47.

Pasternak, R. C., S. C. Smith and C. N. BaireyMerz. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke. 33: 2337-2341.

Pons-Rejraji, H., F. Brugnon, B. Sion, S. Maqdasy, G. Gouby, B. Pereira, G. Marceau, A. Gremeau, J. Drevet, G. Grizard, L. Janny and I. Tauveron. 2014. Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: A pilot prospective clinical trial. Reprod. Biol. Endocrinol. 12: 65-66.

Schmechel, A., M. Grimm, A. H. El Armouche and T. Eschenhagen. 2009. Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovasc. Res. 82(1): 100-106.

Undas, A., K. E. Brummel-Ziedins and K. G. Mann. 2014. Anticoagulant effects of statins and their clinical implications. Thromb. Haemost. 111(3): 392-400.

Vanholder, R., M. S. Sever, E. Erek and N. Lameire. 2000. Rhabdomyolysis. J. Am. Soc. Nephrol. 11(8): 1553-1561.

Wang, Q., Y. Y. Su, Y. Q. Li, Y. F. Zhang, S. Yang, J. L. Wang and H. Y. Li. 2017. Atorvastatin alleviates renal ischemia-reperfusion injury in rats by promoting M1-M2 transition. Mol. Med. Rep. 15(2): 798-804.

Wierzbicki, A. S., J. A. Herd, C. M. Ballantyne and J. A. Farmer. 1999. Thrombotic vascular events after change of statin. Lancet. 353(9155): 845.

Zahr, R. S., P. Chappa, H. Yin, L. A. Brown, K. I. Ataga and D. R. Archer. 2018. Renal protection by atorvastatin in a murine model of sickle cell nephropathy. Br. J. Haematol. 181(1): 111-121.

Published

2019-04-10

How to Cite

Mustafa, T., & Abdulah, H. (2019). Histological Alterations Induced by Atorvastatin Therapeutic Doses in some Organs of Male Albino Rats. Polytechnic Journal, 9(1), 13-16. https://doi.org/10.25156/ptj.v9n1y2019.pp13-16

Issue

Section

Research Articles